[HTML][HTML] Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - BMC psychiatry, 2021 - Springer
Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …
antidepressants (ADs) is approved in the European Union, United States, and other markets …
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a …
N Takahashi, A Yamada, A Shiraishi… - BMC …, 2021 - search.ebscohost.com
Abstract Background: Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …
antidepressants (ADs) is approved in the European Union, United States, and other markets …
Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to oral antidepressants in japanese patients with treatment-resistant depression: A …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - BMC …, 2021 - psycnet.apa.org
Background: Esketamine nasal spray (Spravato) in conjunction with oral antidepressants
(ADs) is approved in the European Union, United States, and other markets for treatment …
(ADs) is approved in the European Union, United States, and other markets for treatment …
[HTML][HTML] Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant …
N Takahashi, A Yamada, A Shiraishi… - BMC …, 2021 - bmcpsychiatry.biomedcentral.com
Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is
approved in the European Union, United States, and other markets for treatment-resistant …
approved in the European Union, United States, and other markets for treatment-resistant …
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - BMC …, 2021 - europepmc.org
Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants
(ADs) is approved in the European Union, United States, and other markets for treatment …
(ADs) is approved in the European Union, United States, and other markets for treatment …
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a …
N Takahashi, A Yamada, A Shiraishi… - BMC …, 2021 - search.proquest.com
Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants
(ADs) is approved in the European Union, United States, and other markets for treatment …
(ADs) is approved in the European Union, United States, and other markets for treatment …
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants
(ADs) is approved in the European Union, United States, and other markets for treatment …
(ADs) is approved in the European Union, United States, and other markets for treatment …
[HTML][HTML] Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - BMC …, 2021 - ncbi.nlm.nih.gov
Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants
(ADs) is approved in the European Union, United States, and other markets for treatment …
(ADs) is approved in the European Union, United States, and other markets for treatment …
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a …
N Takahashi, A Yamada, A Shiraishi, H Shimizu… - BMC …, 2021 - go.gale.com
Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants
(ADs) is approved in the European Union, United States, and other markets for treatment …
(ADs) is approved in the European Union, United States, and other markets for treatment …